213 related articles for article (PubMed ID: 31429781)
21. Safety and Efficacy of Combined Resveratrol and Sirolimus in Lymphangioleiomyomatosis.
Gupta N; Zhang B; Zhou Y; McCormack FX; Ingledue R; Robbins N; Kopras EJ; McMahan S; Singla A; Swigris J; Cole AG; Holz MK
Chest; 2023 May; 163(5):1144-1155. PubMed ID: 36642366
[TBL] [Abstract][Full Text] [Related]
22. A Novel Quantitative Computed Tomographic Analysis Suggests How Sirolimus Stabilizes Progressive Air Trapping in Lymphangioleiomyomatosis.
Argula RG; Kokosi M; Lo P; Kim HJ; Ravenel JG; Meyer C; Goldin J; Lee HS; Strange C; McCormack FX;
Ann Am Thorac Soc; 2016 Mar; 13(3):342-9. PubMed ID: 26799509
[TBL] [Abstract][Full Text] [Related]
23. Correlation of serum vascular endothelial growth factor-D concentration with clinical presentation and course of lymphangioleiomyomatosis.
Radzikowska E; Jaguś P; Sobiecka M; Chorostowska-Wynimko J; Wiatr E; Kuś J; Roszkowski-Śliż K
Respir Med; 2015 Nov; 109(11):1469-75. PubMed ID: 26386638
[TBL] [Abstract][Full Text] [Related]
24. The efficacy and safety of pharmacological treatments for lymphangioleiomyomatosis.
Wang Q; Luo M; Xiang B; Chen S; Ji Y
Respir Res; 2020 Feb; 21(1):55. PubMed ID: 32059669
[TBL] [Abstract][Full Text] [Related]
25. Determinants of Progression and Mortality in Lymphangioleiomyomatosis.
Xu W; Yang C; Cheng C; Wang Y; Hu D; Huang J; He Y; Wang J; Chen K; Yang L; Zhou W; Zhang T; Liu S; Dai J; Meng S; Li X; Yang Y; Wang ST; Feng R; Zhang W; Zhang H; Wang L; Tian X; Xu KF
Chest; 2023 Jul; 164(1):137-148. PubMed ID: 36801466
[TBL] [Abstract][Full Text] [Related]
26. Serum vascular endothelial growth factor-D as a diagnostic and therapeutic biomarker for lymphangioleiomyomatosis.
Hirose M; Matsumuro A; Arai T; Sugimoto C; Akira M; Kitaichi M; Young LR; McCormack FX; Inoue Y
PLoS One; 2019; 14(2):e0212776. PubMed ID: 30818375
[TBL] [Abstract][Full Text] [Related]
27. Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus.
Taveira-DaSilva AM; Hathaway O; Stylianou M; Moss J
Ann Intern Med; 2011 Jun; 154(12):797-805, W-292-3. PubMed ID: 21690594
[TBL] [Abstract][Full Text] [Related]
28. Concentration of Serum Vascular Endothelial Growth Factor (VEGF-D) and Its Correlation with Functional and Clinical Parameters in Patients with Lymphangioleiomyomatosis from a Brazilian Reference Center.
Amaral AF; de Oliveira MR; Dias OM; Arimura FE; Freitas CSG; Acencio MMP; de Alvarenga VA; Kairalla RA; Carvalho CRR; Baldi BG;
Lung; 2019 Apr; 197(2):139-146. PubMed ID: 30623243
[TBL] [Abstract][Full Text] [Related]
29. Effects of sirolimus in lymphangioleiomyomatosis patients on lung cysts and pulmonary function: long-term follow-up observational study.
Kim C; Do KH; Cha J; Song JW; Lee SM; Lee KY
Eur Radiol; 2020 Feb; 30(2):735-743. PubMed ID: 31471750
[TBL] [Abstract][Full Text] [Related]
30. Sirolimus decreases circulating lymphangioleiomyomatosis cells in patients with lymphangioleiomyomatosis.
Cai X; Pacheco-Rodriguez G; Haughey M; Samsel L; Xu S; Wu HP; McCoy JP; Stylianou M; Darling TN; Moss J
Chest; 2014 Jan; 145(1):108-112. PubMed ID: 24051985
[TBL] [Abstract][Full Text] [Related]
31. Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement.
Glasgow CG; Avila NA; Lin JP; Stylianou MP; Moss J
Chest; 2009 May; 135(5):1293-1300. PubMed ID: 19420197
[TBL] [Abstract][Full Text] [Related]
32. A phase II clinical trial of the Safety Of Simvastatin (SOS) in patients with pulmonary lymphangioleiomyomatosis and with tuberous sclerosis complex.
Krymskaya VP; Courtwright AM; Fleck V; Dorgan D; Kotloff R; McCormack FX; Kreider M
Respir Med; 2020 Mar; 163():105898. PubMed ID: 32125970
[TBL] [Abstract][Full Text] [Related]
33. Durability of Sirolimus for Lymphangioleiomyomatosis.
Martirossian A; Shah S; Carrete L; Valle J; Valentine V
Am J Med Sci; 2017 Dec; 354(6):603-607. PubMed ID: 29208258
[TBL] [Abstract][Full Text] [Related]
34. Clinical characteristics in lymphangioleiomyomatosis-related pulmonary hypertension: an observation on 50 patients.
Wu X; Xu W; Wang J; Tian X; Tian Z; Xu K
Front Med; 2019 Apr; 13(2):259-266. PubMed ID: 29675687
[TBL] [Abstract][Full Text] [Related]
35. CA-125 in Disease Progression and Treatment of Lymphangioleiomyomatosis.
Glasgow CG; Pacheco-Rodriguez G; Steagall WK; Haughey ME; Julien-Williams PA; Stylianou MP; Gochuico BR; Moss J
Chest; 2018 Feb; 153(2):339-348. PubMed ID: 28576630
[TBL] [Abstract][Full Text] [Related]
36. Recent advances in the pathobiology and clinical management of lymphangioleiomyomatosis.
Harari S; Spagnolo P; Cocconcelli E; Luisi F; Cottin V
Curr Opin Pulm Med; 2018 Sep; 24(5):469-476. PubMed ID: 29927757
[TBL] [Abstract][Full Text] [Related]
37. Long-term clinical course and outcomes in patients with lymphangioleiomyomatosis.
Yoon HY; Kim HJ; Song JW
Respir Res; 2022 Jun; 23(1):158. PubMed ID: 35717210
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of sirolimus in lymphangioleiomyomatosis.
Burger CD
N Engl J Med; 2011 Jul; 365(3):271-2; author reply 272. PubMed ID: 21774717
[No Abstract] [Full Text] [Related]
39. Risk factors for stomatitis in patients with lymphangioleiomyomatosis during treatment with sirolimus: A multicenter investigator-initiated prospective study.
Kitamura N; Seyama K; Inoue Y; Nagai K; Suzuki M; Moriyama H; Takada T; Tazawa R; Hirai T; Mishima M; Hayashida M; Hirose M; Arai T; Sugimoto C; Hattori N; Watanabe K; Tamada T; Akazawa K; Tanaka T; Nakata K
Pharmacoepidemiol Drug Saf; 2017 Oct; 26(10):1182-1189. PubMed ID: 28752672
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of sirolimus for the prevention of recurrent pneumothorax in patients with lymphangioleiomyomatosis: a case series.
Zhou L; Ouyang R; Luo H; Ren S; Chen P; Peng Y; Liu T; Liu G
Orphanet J Rare Dis; 2018 Sep; 13(1):168. PubMed ID: 30241551
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
